Enliven Therapeutics Ownership | Who Owns Enliven Therapeutics?

Enliven Therapeutics Ownership Summary

Enliven Therapeutics is owned by 21.08% institutional investors, 7.52% insiders, and 71.39% retail investors. Orbimed advisors is the largest institutional shareholder, holding 14.05% of ELVN shares. Polar Capital Healthcare Opports Inc is the top mutual fund, with 4.59% of its assets in Enliven Therapeutics shares.

ELVN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Enliven Therapeutics	21.08%	7.52%	71.39%
Sector	Healthcare Stocks	35.75%	11.89%	52.37%
Industry	Biotech Stocks	36.05%	11.82%	52.13%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Orbimed advisors	7.96M	14.05%	$312.01M
Fmr	6.83M	12.05%	$267.71M
Polar capital	5.07M	8.94%	$198.58M
Blackrock funding, inc. /de	3.68M	6.50%	$144.44M
Commodore capital lp	3.27M	5.78%	$128.38M
Vestal point capital, lp	3.25M	5.74%	$127.40M
Vanguard group	2.80M	4.51%	$43.15M
Bellevue group	2.32M	4.10%	$90.98M
Fairmount funds management	1.86M	3.27%	$72.74M
Citadel advisors	1.74M	3.08%	$68.36M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Commodore capital lp	3.27M	7.43%	$128.38M
Orbimed advisors	7.96M	6.21%	$312.01M
Fairmount funds management	1.86M	5.25%	$72.74M
Exome asset management	220.09K	4.46%	$8.63M
Novo	1.28M	4.07%	$50.18M
Avidity partners management lp	400.00K	3.73%	$16.49M
Vestal point capital, lp	3.25M	3.56%	$127.40M
Stempoint capital lp	363.44K	2.77%	$14.25M
First turn management	623.84K	2.73%	$24.45M
Vr adviser	1.73M	2.53%	$67.67M

Top Buyers

Holder	Shares	% Assets	Change
Bellevue group	2.32M	2.17%	2.32M
Polar capital	5.07M	0.71%	1.55M
Siren	746.23K	0.81%	746.23K
Alliancebernstein	771.88K	0.00%	735.04K
Baker bros. advisors lp	905.19K	0.20%	633.78K

Top Sellers

Holder	Shares	% Assets	Change
Fairmount funds management	1.86M	5.25%	-1.86M
Janus henderson group	11.00K	0.00%	-1.66M
Point72 asset management	-	-	-1.50M
Vr adviser	1.73M	2.53%	-1.50M
Commodore capital lp	3.27M	7.43%	-1.42M

New Positions

Holder	Shares	% Assets	Change	Value
Bellevue group	2.32M	2.17%	2.32M	$90.98M
Siren	746.23K	0.81%	746.23K	$29.25M
Caption management	370.00K	0.08%	370.00K	$14.50M
Capricorn fund managers	369.40K	2.26%	369.40K	$14.48M
Stempoint capital lp	363.44K	2.77%	363.44K	$14.25M

Sold Out

Holder	Change
Clearstead advisors	-5.00
Td capital management	-16.00
Stephens consulting	-20.00
Amundi	-23.00
Group one trading	-34.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	90	-29.13%	11,947,495	-80.85%	21	0.21%	64	-1.54%	17	-62.22%
Dec 31, 2025	85	-36.09%	19,456,209	-67.24%	31	0.34%	42	-46.84%	34	13.33%
Sep 30, 2025	52	-57.72%	9,174,149	-84.56%	17	0.14%	34	-58.02%	10	-56.52%
Jun 30, 2025	122	0.83%	59,425,065	19.12%	114	1.14%	80	23.08%	23	-30.30%
Mar 31, 2025	14	-87.27%	19,292,189	-60.47%	38	0.38%	5	-92.19%	3	-88.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Polar Capital Healthcare Opports Inc	2.80M	4.59%	-
Polar Capital Biotech S Inc	2.14M	3.52%	-
Vanguard Total Stock Mkt Idx Inv	1.62M	2.66%	5.16K
Fidelity Select Health Care	1.15M	1.89%	-100.00K
Fidelity Small Cap Growth	1.07M	1.76%	-
iShares Russell 2000 ETF	943.53K	1.55%	8.74K
Pictet-Biotech P USD	754.73K	1.24%	-72.50K
Fidelity Stock Selector Small Cap	653.09K	1.07%	-
Fidelity Advisor Health Care I	580.00K	0.95%	-48.00K
Fidelity Small Cap Growth K6	569.80K	0.94%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 22, 2026	ORBIMED ADVISORS LLC	-	Sell	$66.47K
Jun 22, 2026	ORBIMED ADVISORS LLC	-	Sell	$35.72M
Jun 22, 2026	ORBIMED ADVISORS LLC	-	Sell	$2.10M
Jun 22, 2026	ORBIMED ADVISORS LLC	-	Sell	$1.13M
Jun 17, 2026	Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sell	$59.00K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	21
2026 Q1	-	21
2025 Q4	-	11
2025 Q3	-	28
2025 Q2	-	28

ELVN Ownership FAQ

Who Owns Enliven Therapeutics?

Enliven Therapeutics shareholders are primarily institutional investors at 21.08%, followed by 7.52% insiders and 71.40% retail investors. The average institutional ownership in Enliven Therapeutics's industry, Biotech Stocks , is 36.05%, which Enliven Therapeutics falls below.

Who owns the most shares of Enliven Therapeutics?

Enliven Therapeutics’s largest shareholders are Orbimed advisors (7.96M shares, 14.05%), Fmr (6.83M shares, 12.05%), and Polar capital (5.07M shares, 8.94%). Together, they hold 35.04% of Enliven Therapeutics’s total shares outstanding.

Does Blackrock own Enliven Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Enliven Therapeutics.

Who is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested?

Commodore capital lp is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.43% of its assets in 3.28M Enliven Therapeutics shares, valued at 128.38M$.

Who is the top mutual fund holder of Enliven Therapeutics shares?

Polar Capital Healthcare Opports Inc is the top mutual fund holder of Enliven Therapeutics shares, with 4.59% of its total shares outstanding invested in 2.8M Enliven Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools